Lonza and Hyglos reach agreement for endotoxin detection patents
Lonza Walkersville, Inc. and Hyglos GmbH announced that they have reached a mutually beneficial global settlement which includes a license agreement for Hyglos under certain Lonza patents in the area of endotoxin detection. Specifically, the agreement allows Hyglos to use recombinant factor C technology protected by Lonza’s patents to produce Hyglos’ own endotoxin products. The agreement also includes the dismissal of the law suit Lonza previously filed against Hyglos.
Other news from the department business & finance
![Newsletter](https://img.chemie.de/assets/bionity/images/newsletter.png)
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.